```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:29:22 ON 09 MAR 2007

=> file biosis embase medlinw caplus
'MEDLINW' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):

ENTER A FILE NAME OR (IGNORE):

ENTER A FILE NAME OR (IGNORE):

ENTER A FILE NAME OR (IGNORE):

YOU HAVE RECEIVED THIS PROMPT MESSAGE  5 CONSECUTIVE TIMES WITHOUT ENTERING A
REQUESTED RESPONSE
The file name entered is incorrect.  At the prompt (=>), enter the
correct file name or enter one of the following default options:

  IGNORE - This option is available when in a multifile environment.
           It removes the incorrect file from the list and continues
           accessing the remaining file names entered.

  END    - This option ends the command and you remain in the previous
           files entered.
The following files are available:
 1MOBILITY    - Global Mobility Database from 1906-present
 2MOBILITY    - Global Mobility Standards Database
 ABI-INFORM   - Business Information from 1971 to present
 ADISCTI      - Adis Clinical Trials Insight
 ADISINSIGHT  - Adis R&D Insight 1986-present
 ADISNEWS     - Adis Newsletters 1983-present
 AEROSPACE    - Aerospace and High Technology Database 1962-present
 AGRICOLA     - AGRICulture OnLine Access from 1970 - present
 ALUMINIUM    - Aluminium Industry Abstracts 1968 to the present
 ANABSTR      - Analytical Abstracts
 ANTE         - Abstr. in New Technologies and Eng. 1981 - present
 APOLLIT      - APPLIED POLYMERS LITERATURE 1973-present
 AQUALINE     - Aqualine 1960 to the present
 AQUASCI      - Aquatic Sciences & Fisheries Abstracts 1978-present
 AQUIRE       - Acquatic Toxicity Information Retrieval
 BABS         - BEILSTEIN Abstracts 1980-present
 BEILSTEIN    - BEILSTEIN File of Organic Compounds
 BIBLIODATA   - GERMAN NATIONAL BIBLIOGRAPHY FROM 1945 - PRESENT
 BIOENG       - Biotechnology and Bioengineering database 1982 - pres.
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 14	DEC 18	CA/CAplus patent kind codes updated
NEWS 15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 24	JAN 29	PHAR reloaded with new search and display fields
NEWS 25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 26	FEB 13	CASREACT coverage to be extended
NEWS 27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 30	Feb 26	MEDLINE reloaded with enhancements
NEWS 31	Feb 26	EMBASE enhanced with Clinical Trial Number field
NEWS 32	Feb 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 33	Feb 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 34	Feb 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

BIOSIS - The BIOSIS Previews(R)/RN File 1969-present
BIOTECHABS - Derwent Biotechnology Resource 1982-present
BIOTECHDS - Derwent Biotechnology Resource 1982-present (Subsc.)
BIOTECHNO - BIOTECHNOBASE 1980 TO 2003
CA - The Chemical Abstracts File 1907-present
CABA - CAB ABSTRACTS 1973-present
CAOLD - The pre-1967 Chemical Abstracts File
CAPLUS - The Chemical Abstracts Plus File 1907-present
CASREACT - The Chemical Abstracts Reaction Search Service
CBNB - Chemical Business NewsBase from 1984-present
CEABA-VTB - Chem Eng and Biotech Abstr - Verfahrenstechn Ber 1966-
CERAB - Ceramic Abstracts/World Ceramic Abstracts from 1975
CHEMCATS - CHEMICAL CATALOGS ONLINE 1993-to the present
CHEMINFORMRX - The CHEMINFORMRX Reaction Search Service
CHEMLIST - Regulated Chemicals Listing
CHEMSAFE - CHEMSAFE - chemical safety information
CIN - The Chemical Industry Notes File for 1974-present
CIVILENG - Civil Engineering Abstracts 1966 to the present
COMPENDEX - COMPENDEX*PLUS File from 1970 - present
COMPUAB - Computer & Information Systems Abstracts 1981-present
COMPUSCIENCE - COMPUTERSCIENCE FROM 1972-2002
CONFSCI - Conference Papers Index from 1973-present
COPPERLIT - Copper Literature Database
CORROSION - Corrosion Abstracts 1980 to the present
CROPB - Derwent Crop Protection File 1968 - 1984
CROPR - Derwent Crop Protection Registry
CROPU - DERWENT CROP PROTECTION FILE 1985 - 2003
CSCHEM - ChemSources - USA and International (Chemicals)
CSCORP - ChemSources - USA and International (Company Directory
CSNB - Chemical Safety News Base from 1981-present
DDFB - Derwent Drug File, Backfile 1964 - 1982
DDFU - Derwent Drug File from 1983 - present
DETHERM - DETHERM-DECHEMA thermophysical property database
DGENE - Derwent Geneseq Database 1981 - present
DISSABS - Dissertation Abstracts from 1861 to present
DJSMDS - Derwent Reaction Search Service DJSM (Subscribers)
DJSMONLINE - Derwent Reaction Search Service DJSM
DKF - The German Automotive Engineering Database 1974-date
DPCI - Derwent Patents Citation Index 1978 to present
DRUGB - Derwent Drug File, Backfile 1964 - 1982 (Subscribers)
DRUGMONOG - IMS Product Monographs (Approved Pharm. Industry Users
DRUGMONOG2 - IMS Product Monographs
DRUGU - Derwent Drug File from 1983-present (Subscribers)
ELCOM - Electronics & Communications Abstracts 1981-present
EMA - Engineered Materials Abstracts File from 1986-present
EMBAL - EMBASE Alert
EMBASE - EMBASE File from 1974-present
ENCOMPLIT - EnCompass Literature File 1964-present (Supporters)
ENCOMPLIT2 - EnCompass Literature File 1964-Present (Non-Supporters
ENCOMPPAT - EnCompass Patent File 1964-present (Supporters)
ENCOMPPAT2 - EnCompass Patent File 1964-Present (Non-Supporters)
ENERGY - DOE ENERGY file from 1974-present
ENVIROENG - Environmental Engineering Abstracts 1990 - present
EPFULL - European Patents Fulltext database
ESBIOBASE - Elsevier Biobase 1994 to the present
FOMAD - FOODLINE MARKET 1982 TO PRESENT
FOREGE - FOODLINE LEGAL
FORIS - Research in social sciences from 1996 - 2005
FRANCEPAT - The French Patent Database from 1966 - present
FRFULL - French Patent Full Text from 1980 - present
FROSTI - FOODLINE SCIENCE 1972 TO PRESENT
FSTA - Food Science Technology Abstracts from 1969 - present
GBFULL - United Kingdom (GB) Patents Full Text from 1979 - pres
GENBANK - Genetic Sequence Data Bank

GEOREF - Geological Reference File 1785-present
GMELIN97 - Gmelin Handb. of Inorg. Chem. + Sci. Publ. 1817-1997
HCA - CA File with hour-based pricing
HCAOLD - Pre-1967 CA File with hour-based pricing
HCAPLUS - CAPLUS File with hour-based pricing
HCHEMLIST - Regulated Chemicals Listing with hour-based pricing
HCIN - The CIN File for 1974-present with hour-based pricing
HEALSAFE - Health and Safety Science Abstracts 1981-present
HOME - The default login file. Contains no data.
HSDB - Hazardous Substances Databank
ICONDA - International Construction Database from 1976-present
ICSD - ICSD - Inorganic Crystal Structure Data File
IFICDB - The IFI Comprehensive Database from 1950-present
IFICLS - The IFI Current Patent Legal Status Database
IFIPAT - The IFI Patent Database from 1950-present
IFIREF - The IFI Uniterm and U.S. Class Reference File
IFIUDB - The IFI Uniterm Database from 1950-present
IMSCOPROFILE - IMS Company Profiles 1995-present
IMSCOSEARCH - IMS Company Search
IMSDRUGCONF - IMSworld Pharmaceutical Meetings Diary
IMSDRUGNEWS - IMS Drug News 1991-present
IMSPATENTS - IMS LifeCycle, Patent Focus with Patent Family Data
IMSPRODUCT - IMS LifeCycle, New Product Focus from 1982-present
IMSRESEARCH - IMS LifeCycle, R&D Focus 1977-present
INFODATA - Information Science and Work from 1976 to present
INIS - International Nuclear Information System 1970-present
INPADOC - The International Patent Database from 1968-present
INSPEC - INSPEC file from 1898 - present
INSPHYS - INSPHYS - Inspec Phys Supplement Backfile (1979 - 1994
IPA - International Pharmaceutical Abstracts 1970-present
ITRD - International Transport Research Documentation 1972-da
JAPIO - JAPIO - Japanese Patents from 1976 - present
JICST-EPLUS - JICST-EPlus File on Sci. & Tech. in Japan 1985-present
KOREAPAT - Korean Patent Abstracts Database from 1979 - present
KOSMET - Cosmetic & Perfume Science & Technology 1968-present
LBIBLIO - Bibliodata learning File
LCA - The CA Learning File
LCASREACT - The CAS Reaction Search Service Learning File
LDPCI - Derwent Patents Citation Index Learning File
LDRUG - Derwent Drug Learn File
LEMBASE - The EMBASE Learning File
LIFESCI - CSA Life Sciences Collection from 1978-present
LINSPEC - Learning INSPEC File
LISA - Library and Information Science Abstracts 1969 - pres.
LITALERT - The Patent Litigation Database from 1973 - present
LMARPAT - The CAS Patent Markush Learning File
LMEDLINE - The MEDLINE Learning File
LPATDPA - The PATDPA Learning File
LREGISTRY - The Registry Learning File.
LWPI - Derwent World Patents Index Learning File
MARPAT - The CAS Patent Markush File 1988-present
MATBUS - Materials Business File from 1983-present
MDF - Metals Datafile
MECHENG - Mechanical and Transportation Eng. Abs. 1966-
MEDLINE - MEDlars onLINE File from 1960 - present
METADEX - METADEX File from 1966-present
MRCK - The Merck Index Online (SM)
MSDS-CCOHS - CCOHS Material Safety Data Sheets
MSDS-OHS - Material Safety Data Sheets - OHS
NAPRALERT - Natural Products Alert Database
NLDB - Newsletter Database from 1988 - present
NTIS - U.S.Government Reports Announcements 1964-present
NUTRACEUT - Nutraceuticals International 1996 to the present
OCEAN - Oceanic Abstracts from 1964 - current

GEOREF - Geological Reference File 1785-present
GMELIN97 - Gmelin Handb. of Inorg. Chem. + Sci. Publ. 1817-1997
HCA - CA File with hour-based pricing
HCAOLD - Pre-1967 CA File with hour-based pricing
HCAPLUS - CAPLUS File with hour-based pricing
HCHEMLIST - Regulated Chemicals Listing with hour-based pricing
HCIN - The CIN File for 1974-present with hour-based pricing
HEALSAFE - Health and Safety Science Abstracts 1981-present
HOME - The default login file. Contains no data.
HSDB - Hazardous Substances Databank
ICONDA - International Construction Database from 1976-present
ICSD - ICSD - Inorganic Crystal Structure Data File
IFICDB - The IFI Comprehensive Database from 1950-present
IFICLS - The IFI Current Patent Legal Status Database
IFIPAT - The IFI Patent Database from 1950-present
IFIREF - The IFI Uniterm and U.S. Class Reference File
IFIUDB - The IFI Uniterm Database from 1950-present
IMSCOPROFILE - IMS Company Profiles 1995-present
IMSCOSEARCH - IMS Company Search
IMSDRUGCONF - IMSworld Pharmaceutical Meetings Diary
IMSDRUGNEWS - IMS Drug News 1991-present
IMSPATENTS - IMS LifeCycle, Patent Focus with Patent Family Data
IMSPRODUCT - IMS LifeCycle, New Product Focus from 1982-present
IMSRESEARCH - IMS LifeCycle, R&D Focus 1977-present
INFODATA - Information Science and Work from 1976 to present
INIS - International Nuclear Information System 1970-present
INPADOC - The International Patent Database from 1968-present
INSPEC - INSPEC file from 1898 - present
INSPHYS - INSPHYS - Inspec Phys Supplement Backfile (1979 - 1994
IPA - International Pharmaceutical Abstracts 1970-present
ITRD - International Transport Research Documentation 1972-da
JAPIO - JAPIO - Japanese Patents from 1976 - present
JICST-EPLUS - JICST-EPlus File on Sci. & Tech. in Japan 1985-present
KOREAPAT - Korean Patent Abstracts Database from 1979 - present
KOSMET - Cosmetic & Perfume Science & Technology 1968-present
LBIBLIO - Bibliodata learning File
LCA - The CA Learning File
LCASREACT - The CAS Reaction Search Service Learning File
LDPCI - Derwent Patents Citation Index Learning File
LDRUG - Derwent Drug Learn File
LEMBASE - The EMBASE Learning File
LIFESCI - CSA Life Sciences Collection from 1978-present
LINSPEC - Learning INSPEC File
LISA - Library and Information Science Abstracts 1969 - pres.
LITALERT - The Patent Litigation Database from 1973 - present
LMARPAT - The CAS Patent Markush Learning File
LMEDLINE - The MEDLINE Learning File
LPATDPA - The PATDPA Learning File
LREGISTRY - The Registry Learning File.
LWPI - Derwent World Patents Index Learning File
MARPAT - The CAS Patent Markush File 1988-present
MATBUS - Materials Business File from 1983-present
MDF - Metals Datafile
MECHENG - Mechanical and Transportation Eng. Abs. 1966-
MEDLINE - MEDlars onLINE File from 1960 - present
METADEX - METADEX File from 1966-present
MRCK - The Merck Index Online (SM)
MSDS-CCOHS - CCOHS Material Safety Data Sheets
MSDS-OHS - Material Safety Data Sheets - OHS
NAPRALERT - Natural Products Alert Database
NLDB - Newsletter Database from 1988 - present
NTIS - U.S.Government Reports Announcements 1964-present
NUTRACEUT - Nutraceuticals International 1996 to the present
OCEAN - Oceanic Abstracts from 1964 - current

PAPERCHEM2 - Elsevier Engineering Information, Inc. File 1967 - pre
PASCAL - PASCAL 1977 to the present
PATDD - East German Patents from 1982-present
PATDPA - The German Patent Database from 1968-present
PATDPAFULL - The German Full-Text Patent Database from 1987-present
PATDPASPC - German SPC for Drugs and Plant Protecting Agents 1992-
PATIPC - International Patent Classification and Catchword Inde
PCTFULL - WIPO/PCT Patents Full Text 1978 to the present
PCTGEN - PCTGEN: World Patent Application Biosequences
PHAR - Pharmaprojects drug development status file
PHARMAML - Pharma Marketletter 1992 to the present
PHIC - Pharmaceutical & Healthcare Industry News (Current)
PHIN - Pharmaceutical & Healthcare Industry News Archive 1980
PIRA - PIRA & PAPERBASE Database from 1975
POLLUAB - Pollution Abstracts from 1970-present
PROMT - PROMT from 1978 - present
PROUSDDR - Drug Data Report from Prous Science
PS - Pharmaceutical Substances
RAPRA - Rubber, Plastics, Polymer Composites 1972 - present
RDISCLOSURE - Research Disclosure 1960 to the present
REGISTRY - The CAS Registry File of substances
RSWB - Regional planning and building construction
RTECS - Registry of Toxic Effects of Chemical Substances
RUSSIAPAT - RUSSIAN PATENT ABSTRACTS DATABASE FROM 1924 - PRESENT
SCISEARCH - ISI Science Citation Index from 1974 - present
SOLIDSTATE - Solid State and Superconductivity Abstracts from 1981
SOLIS - German literature in social sciences 1945-present
SPECINFO - Spectral Database Information System
STNGUIDE - Descriptive information about STN databases
STNMAIL - STN Electronic Mail Service
SYNTHLINE - Synthline Drug Synthesis Database 1984-present
TEMA - TEMA: Technology and Management 1990 to the present
TEXTILETECH - Textile Technology Digest from 1978 to the present
TOXCENTER - Toxicology Center from 1907 - present
TRIBO - TRIBOLOGY INDEX (Friction,Wear,Lubrication) 1972-pres.
TULSA - Petroleum Abstracts 1965-present
TULSA2 - Petroleum Abstracts 1965-present (Non-subscribers)
UFORDAT - Environment Research in Progress from 1974 - present
ULIDAT - Environmental Literature from 1976-present
USAN - USAN - United States Adopted Names
USPAT2 - U.S. Patents Latest Publications from 2001 - present
USPATFULL - U.S. Patents Original Publications from 1971 - present
VETB - Derwent Veterinary Drug File 1968 - 1982
VETU - Derwent Veterinary Drug File 1983 - 2001
WATER - Water Resource Abstracts 1967 to the present
WELDASEARCH - Weldasearch 1967 to the present
WPIDS - Derwent World Patents Index 1963 - present (Subscr.)
WPIFV - WPIFV - DERWENT WORLD PATENT INDEX FIRST VIEW
WPINDEX - Derwent World Patents Index 1963 - present
WPIX - DERWENT WPI WITH EXTENSION ABSTRACTS 1963 - PRESENT
WSCA - World Surface Coatings Abstracts 1976 - present
WTEXTILES - WORLD TEXTILES 1970 TO THE PRESENT
ZCA - CA File with zero connect hour pricing
ZCAPLUS - CAPLUS File with zero connect hour pricing
ZREGISTRY - Zero connect hour REGISTRY

To look at detailed information about a file, first access that file using the FILE command. Enter "HELP CONTENT" at an arrow prompt (=>) for a general description of the file. Enter "HELP DIRECTORY" for a list of help messages available for that file. The database summary sheet is also available for the file in STNGUIDE. Enter "FILE STNGUIDE" at an arrow prompt (=>), then search the file name in the /DBN search field. You can then display the search fields, display fields, file content, sources, etc.

```
All files are available for multifile searching except HOME,
STNGUIDE, STNMAIL, and the Learning Files.
IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK
ENTER A FILE NAME OR (IGNORE):

ENTER A FILE NAME OR (IGNORE):

ENTER A FILE NAME OR (IGNORE):

ENTER A FILE NAME OR (IGNORE):end

=> file caplus medline biosis embase
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.42       0.42

FILE 'CAPLUS' ENTERED AT 12:30:17 ON 09 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:30:17 ON 09 MAR 2007

FILE 'BIOSIS' ENTERED AT 12:30:17 ON 09 MAR 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:30:17 ON 09 MAR 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

=> e extracoporeal
E1            1     EXTRACOPORE/BI
E2            1     EXTRACOPOREA/BI
E3          124 --> EXTRACOPOREAL/BI
E4            1     EXTRACOPPOREAL/BI
E5            1     EXTRACOPREAL/BI
E6            1     EXTRACOPROEAL/BI
E7            4     EXTRACOPROREAL/BI
E8            1     EXTRACOPRPOREAL/BI
E9           19     EXTRACOPY/BI
E10           6     EXTRACOPYING/BI
E11           5     EXTRACOR/BI
E12           1     EXTRACORAL/BI

=> s e3
L1          124 EXTRACOPOREAL/BI

=> s aromatic
L2       614937 AROMATIC

=> s trifunctional
L3         5500 TRIFUNCTIONAL

=> s L2 and L3
L4          317 L2 AND L3

=> s biotin
L5        86694 BIOTIN

=> s L4 and L5
L6            1 L4 AND L5

=> d 1 L6 ibib abs
```

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:861452 CAPLUS
DOCUMENT NUMBER: 134:29252
TITLE: Synthesis of water soluble multi-biotin -containing compounds for use in targeting biotin-binding proteins
PATENT ASSIGNEE(S): University of Washington, USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000072802	A2	20001207	WO 2000-US15081	20000601
WO 2000072802	A3	20020207		
W: AU, BR, CA, IL, JP, KR, MX, RU				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1196199	A2	20020417	EP 2000-938025	20000601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1999-324267 A 19990602
WO 2000-US15081 W 20000601

AB Syntheses of water soluble discrete multi-biotin-containing compds. with at least three biotin moieties are disclosed. The water soluble biotin-containing compds. may addnl. comprise one or more moieties that confer resistance to cleavage by biotinidase or that is cleavable in vitro or in vivo. The discrete multi-biotin-containing compds. may include a reactive moiety that provides a site for reaction with yet another moiety, such as a targeting, diagnostic or therapeutic functional moiety. Biotinylation reagents comprising water soluble linker moieties are also disclosed and may addnl. comprise a biotinidase protective group. Methods for amplifying the number of sites for binding biotin-binding proteins at a selected target using multi-biotin compds. are also disclosed.

```
=> e aminoisophthalic
E1            2     AMINOISOPHTHALDIAMIDE/BI
E2            1     AMINOISOPHTHALDIAMIDES/BI
E3          493 --> AMINOISOPHTHALIC/BI
E4           13     AMINOISOPHTHALONITRILE/BI
E5            2     AMINOISOPHTHALONITRILES/BI
E6           11     AMINOISOPHTHALOYL/BI
E7            1     AMINOISOPHTHALOYLBIS/BI
E8            1     AMINOISOPHTHALOYLDIGLYCINE/BI
E9            1     AMINOISOPHTHALYLIDENE/BI
E10           1     AMINOISOPHTHATIC/BI
E11           1     AMINOISOPHTHLATO/BI
E12           1     AMINOISOPIMPINELLIN/BI

=> s e3
L7          493 AMINOISOPHTHALIC/BI

=> s biotin
L8        86694 BIOTIN

=> s L7 and L8
L9           13 L7 AND L8

=> dup rem L9
```

```
PROCESSING COMPLETED FOR L9
L10          11 DUP REM L9 (2 DUPLICATES REMOVED)

=> s L3 and L5
L11          79 L3 AND L5

=> dup rem L11
PROCESSING COMPLETED FOR L11
L12          44 DUP REM L11 (35 DUPLICATES REMOVED)

=> s L12 and aromatic
L13          1 L12 AND AROMATIC

=> d L10 1-11 ibib abs

L10  ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2006:1124832  CAPLUS
DOCUMENT NUMBER:         145:443804
TITLE:                   Amphiphilic polymers and methods of use thereof
INVENTOR(S):             Colton, Clark K.; Watterson, Arthur; Kumar, Rajesh;
                         Parmar, Virinder S.; Fisher, Robert; Kumar, Jayant
PATENT ASSIGNEE(S):      Massachusetts Institute of Technology, USA
SOURCE:                  PCT Int. Appl., 127pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2006113666         A2    20061026    WO 2006-US14483         20060417
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     US 2006269479         A1    20061130    US 2006-405012          20060417
PRIORITY APPLN. INFO.:                       US 2005-672533P      P  20050419
                                             US 2005-672856P      P  20050420
                                             US 2005-732633P      P  20051103
AB   The present invention relates to amphiphilic polymers, and micelles and
     compns. comprising the same, and their use in a variety of biol. settings,
     including imaging, targeting drugs, or a combination thereof for
     diagnostic and therapeutic purposes.  A PEG oligomer, for example, is
     polymerized with a trifunctional linking mol. (di-Me 5-hydroxyisophthalate)
     using lipase B which leaves the phenolic hydroxy group available for
     further chemical reaction.  The PEG may be further modified with
     perfluorododecanol, fluorescent probes, targeting peptides, etc.  The
     resulting multimodal agent is used for imaging tumors, such as human
     epithelial cell adenocarcinomas which overexpress uMUC-1 antigen.

L10  ANSWER 2 OF 11  BIOSIS  COPYRIGHT (c) 2007 The Thomson Corporation  on STN
ACCESSION NUMBER:    2002:583437  BIOSIS
DOCUMENT NUMBER:     PREV200200583437
TITLE:               Trifunctional conjugation reagents. Reagents that contain a
                     biotin and a radiometal chelation moiety for
```

application to extracorporeal affinity adsorption of radiolabeled antibodies.

AUTHOR(S): Wilbur, D. Scott [Reprint author]; Chyan, Ming-Kuan; Hamlin, Donald K.; Kegley, Brian B.; Nilsson, Rune; Sandberg, Bengt E. B.; Brechbiel, Martin

CORPORATE SOURCE: Department of Radiation Oncology, University of Washington, 2121 N. 35th Street, Seattle, WA, 98103-9103, USA
dswilbur@u.washington.edu

SOURCE: Bioconjugate Chemistry, (September-October, 2002) Vol. 13, No. 5, pp. 1079-1092. print.
CODEN: BCCHES. ISSN: 1043-1802.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 13 Nov 2002
Last Updated on STN: 13 Nov 2002

AB A method of removing radiolabeled monoclonal antibodies (mAbs) from blood using a device external to the body, termed extracorporeal affinity-adsorption (EAA), is being evaluated as a means of decreasing irradiation of noncancerous tissues in therapy protocols. The EAA device uses an avidin column to capture biotinylated-radiolabeled mAbs from circulated blood. In this investigation, three trifunctional reagents have been developed to minimize the potential deleterious effect on antigen binding brought about by the combination of radiolabeling and biotinylation of mAbs required in the EAA approach. The studies focused on radiolabeling with 111In and 90Y, so the chelates CHX-A"-DTPA and DOTA, which form stable attachments to these radionuclides, were incorporated in the trifunctional reagents. The first trifunctional reagent prepared did not incorporate a group to block the biotin cleaving enzyme biotinidase, but the two subsequent reagents coupled aspartic acid to the biotin carboxylate for that purpose. All three reagents used 4,7,10-trioxa-1,13-tridecanediamine as water-soluble spacers between an aminoisophthalate core and the biotin or chelation group. The mAb conjugates were radioiodinated to evaluate cell binding as a function of substitution. Radioiodination was used so that a direct comparison with unmodified mAb could be made. Evaluation of the number of conjugates per antibody versus cell binding immunoreactivities indicated that minimizing the number of conjugates was best. Interestingly, a decrease of radioiodination yield as a function of the number of isothiocyanate containing conjugates per mAb was noted. The decreased yields were presumably due to the presence of thiourea functionality formed in the conjugation reaction. Radiolabeling with 111In and 90Y was facile at room temperature for conjugates containing the CHX-A", but elevated temperature (e.g., 45degreeC) was required to obtain good yields with the DOTA chelate. Stability of 90Y labeled mAb in serum, and when challenged with 10 mM EDTA, was high. However, challenging the 90Y labeled mAb with 10 mM DTPA demonstrated high stability for the DOTA containing conjugate, but low stability for the CHX-A" containing conjugate. Thus, the choice between these two chelating moieties might be made on requirements for facile and gentle labeling versus very high in vivo stability. Application of the trifunctional biotinylation reagents to the blood clearance of labeled antibodies in EAA is under investigation. The new reagents may also be useful for other applications.

L10 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:923565 CAPLUS

DOCUMENT NUMBER: 136:42919

TITLE: Biotin derivatives for an extracorporeal device

INVENTOR(S): Sandberg, Bengt; Wilbur, Scott; Nilsson, Rune

PATENT ASSIGNEE(S): Mitra Medical Technology AB, Swed.; University of Washington

SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095857	A2	20011220	WO 2001-SE1374	20010618
WO 2001095857	A3	20020328		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002159994	A1	20021031	US 2001-881213	20010615
CA 2412495	A1	20011220	CA 2001-2412495	20010618
AU 2001074761	A5	20011224	AU 2001-74761	20010618
EP 1289563	A2	20030312	EP 2001-941404	20010618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011726	A	20030527	BR 2001-11726	20010618
JP 2004503299	T	20040205	JP 2002-510039	20010618
HU 200401953	A2	20041228	HU 2004-1953	20010618
RU 2279896	C2	20060720	RU 2003-101060	20010618
NO 2002005931	A	20030214	NO 2002-5931	20021211
US 2004052784	A1	20040318	US 2003-311150	20030423
PRIORITY APPLN. INFO.:			SE 2000-2287 A	20000616
			US 2000-216625P P	20000707
			WO 2001-SE1374 W	20010618

AB A method for the conditioning of an extracorporeal device is described, as well as a method for extracorporeal extraction of toxic material from mammalian body fluids in connection with diagnosis or treatment of a mammalian condition or disease. The methods comprise (i) a solution containing a reagent comprising biotin moieties, such as natural biotin or its derivs., and a toxin-binding moiety, (ii) linkers and a trifunctional crosslinking moiety, and (ii) an extracorporeal device comprising said reagent. For example, a dibiotin compound, 1-isothiocyanato-3,5-bis-(13'-biotinamidyl-4',7',10'-trioxatridecanamidyl)-aminoisophthalate was prepared and conjugated with a toxin-binding mol., i.e., monoclonal antibody 53-6A2. A dibiotin-toxin-binding conjugate was used for conditioning of an avidin-agarose column suitable for removal of toxins from blood.

L10 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:109400 CAPLUS
DOCUMENT NUMBER: 130:177546
TITLE: Methods of receptor modulation and therapeutic and diagnostic uses therefor
INVENTOR(S): Morgan, A. Charles, Jr.; Wilbur, D. Scott
PATENT ASSIGNEE(S): Receptagen Corporation, USA; University of Washington
SOURCE: U.S., 47 pp., Cont.-in-part of U.S. Ser. No. 224,831, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5869465	A	19990209	US 1995-406194	19950316
CA 2187346	A1	19951019	CA 1995-2187346	19950407

WO 9527723	A1	19951019	WO 1995-US4404		19950407
W: AU, CA, JP, KR, NO, NZ					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9522835	A	19951030	AU 1995-22835		19950407
EP 754189	A1	19970122	EP 1995-916284		19950407
EP 754189	B1	20021009			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
JP 10502334	T	19980303	JP 1995-526497		19950407
AT 225799	T	20021015	AT 1995-916284		19950407
US 5840712	A	19981124	US 1995-545151		19951019
US 6083926	A	20000704	US 1998-200422		19981123
PRIORITY APPLN. INFO.:			US 1994-224831	B2	19940408
			US 1995-406191	A	19950316
			US 1995-406192	A	19950316
			US 1995-406194	A	19950316
			WO 1995-US4404	W	19950407
			US 1995-545151	A3	19951019

AB Receptor-modulating agents capable of modulating cell surface receptors by affecting the cell-surface receptor trafficking pathway are utilized for the treatment and diagnosis of a variety of disorders in warm-blooded animals, including neoplastic disorders. The receptor-modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety. Synthesis of several receptor-modulating agents using different functional classes of rerouting moieties is described. More specifically, a series of examples are presented which employ vitamin B12 as a targeting moiety in a receptor-modulating agent.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 1999:668186 CAPLUS
DOCUMENT NUMBER: 132:46430
TITLE: Molecular Necklaces. Cross-Linking Hemoglobin with Reagents Containing Covalently Attached Ligands
AUTHOR(S): Crapatureanu, Sanda; Serbanescu, Ruxandra; Brevitt, Sharon Bisley; Kluger, Ronald
CORPORATE SOURCE: Lash Miller Laboratories Department of Chemistry, University of Toronto, Toronto, ON, M5S 3H6, Can.
SOURCE: Bioconjugate Chemistry (1999), 10(6), 1058-1067
CODEN: BCCHES; ISSN: 1043-1802
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 132:46430

AB Hb can be cross-linked and converted to a bioconjugate in one step by a mol. necklace, a reagent that contains two reacting sites and a pendant ligand. The compound to be conjugated is activated as an electrophile. The activated material is then combined with a reagent (3-aminoisophthalic acid) that contains a nucleophilic (amino) site and two latent (carboxyl) sites. The latent sites of the product are activated as 3,5-dibromosalicylates to produce the cross-linker. Illustrative examples of crosslinking are presented with pendant biotin [bis(3,5-dibromosalicyl) N-biotinyl-5-aminoisophthalate] and pendant N-trifluoroacetyl-L-isoleucylglycine [bis(3,5-dibromosalicyl) N-(N-trifluoroacetyl-L-isoleucylglycyl)-5-aminoisophthalate]. The resulting modified Hbs contain two principal types of cross-link: (β-Lys-82-β'-Lys-82) and (α-Lys-99-α'-Lys-99). The functional properties of the modified Hb containing biotin in a (β-Lys-82-β'-Lys-82) cross-link are (pH 7.4, 55 μM heme, 25 °C, 0.1 M chloride, and 50 mM Bis-Tris) P50 = 4.9 Torr, n50 = 3.0, values which are approx. the same as for native Hb. The results of affinity chromatog. of the biotinylated cross-linked Hb using a column of immobilized avidin indicate that the pendant biotin is much less accessible than free biotin. We suggest that the results are

consistent with the pendant species being strongly attracted into the Hb environment.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:776598 CAPLUS
DOCUMENT NUMBER: 130:38641
TITLE: Preparation of water soluble vitamin B12 as antiinflammatory receptor modulating agents
INVENTOR(S): Morgan, A. Charles, Jr.; Wilbur, D. Scott; Pathare, Pradip M.
PATENT ASSIGNEE(S): Receptagen Corporation, USA; University of Washington
SOURCE: U.S., 66 pp., Cont.-in-part of U.S. Ser. No. 406,191.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5840712	A	19981124	US 1995-545151	19951019
US 5739287	A	19980414	US 1995-406192	19950316
US 5840880	A	19981124	US 1995-406191	19950316
US 5869465	A	19990209	US 1995-406194	19950316
WO 9714711	A1	19970424	WO 1996-US16672	19961018
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
AU 9677182	A	19970507	AU 1996-77182	19961018
EP 1015475	A1	20000705	EP 1996-940247	19961018
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 323127	A	20010330	NZ 1996-323127	19961018
US 6083926	A	20000704	US 1998-200422	19981123

PRIORITY APPLN. INFO.:		
US 1994-224831	B2	19940408
US 1995-406191	A2	19950316
US 1995-406192	A2	19950316
US 1995-406194	A2	19950316
WO 1995-US4404	A2	19950407
US 1995-545151	A	19951019
US 1995-545496	A	19951019
WO 1996-US16672	W	19961018

OTHER SOURCE(S): MARPAT 130:38641

AB Vitamin B12 antiinflammatory receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are disclosed. The vitamin B12 receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety linked by a water-solubilizing linker. Synthesis of a vitamin B12/biotin conjugate and fusion protein receptor modulating agent is reported.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:236288 CAPLUS
DOCUMENT NUMBER: 128:295003
TITLE: Preparation of biotinylated cobalamins as antiinflammatory agents and transcobalamin II

receptors
INVENTOR(S): Wilbur, D. Scott; Pathare, Pradip M.; Morgan, A. Charles, Jr.
PATENT ASSIGNEE(S): University of Washington, USA; Receptagen Corp.
SOURCE: U.S., 58 pp., Cont.-in-part of U.S. Ser. No. 224,831, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5739287	A	19980414	US 1995-406192	19950316
CA 2187346	A1	19951019	CA 1995-2187346	19950407
WO 9527723	A1	19951019	WO 1995-US4404	19950407
W: AU, CA, JP, KR, NO, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9522835	A	19951030	AU 1995-22835	19950407
EP 754189	A1	19970122	EP 1995-916284	19950407
EP 754189	B1	20021009		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10502334	T	19980303	JP 1995-526497	19950407
AT 225799	T	20021015	AT 1995-916284	19950407
US 5840712	A	19981124	US 1995-545151	19951019
US 6083926	A	20000704	US 1998-200422	19981123

PRIORITY APPLN. INFO.:

US 1994-224831	B2	19940408
US 1995-406191	A	19950316
US 1995-406192	A	19950316
US 1995-406194	A	19950316
WO 1995-US4404	W	19950407
US 1995-545151	A3	19951019

AB A biotinylated cobalamin, formed from a vitamin B12 mol. coupled to a biotin mol., is disclosed. In a preferred embodiment, the vitamin B12 mol. is cyanocobalamin. The biotin mol. can also be coupled to a rerouting moiety, optionally through a biotin binding protein such as avidin or streptavidin. The biotinylated cobalamin binds to a cell surface receptor, is invaginated, and once internalized affects the receptor trafficking pathway.
REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:377886 CAPLUS
DOCUMENT NUMBER: 126:343813
TITLE: Preparation of vitamin B12 receptor modulating agents
INVENTOR(S): Morgan, A. Charles, Jr.; Wilbur, D. Scott; Pathare, Pradip M.
PATENT ASSIGNEE(S): Receptagen Corporation, USA; University of Washington; Morgan, A. Charles, Jr.; Wilbur, D. Scott; Pathare, Pradip, M.
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9714711	A1	19970424	WO 1996-US16672	19961018
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG

US 5840712	A	19981124	US 1995-545151		19951019
AU 9677182	A	19970507	AU 1996-77182		19961018
EP 1015475	A1	20000705	EP 1996-940247		19961018
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
NZ 323127	A	20010330	NZ 1996-323127		19961018
PRIORITY APPLN. INFO.:			US 1995-545151	A	19951019
			US 1995-545496	A	19951019
			US 1994-224831	B2	19940408
			US 1995-406191	A2	19950316
			US 1995-406192	A2	19950316
			US 1995-406194	A2	19950316
			WO 1996-US16672	W	19961018

OTHER SOURCE(S): MARPAT 126:343813

AB Vitamin B12 receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are disclosed. The vitamin B12 receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety linked by a water-solubilizing linker.

L10 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	1997:251007 CAPLUS
DOCUMENT NUMBER:	126:238622
TITLE:	A new achiral linker reagent for the incorporation of multiple amino groups into oligonucleotides
INVENTOR(S):	Behrens, Carsten; Petersen, Kenneth H.; Egholm, Michael; Nielsen, John; Dahl, Otto
PATENT ASSIGNEE(S):	Behrens, Carsten, Den.; Petersen, Kenneth H.; Egholm, Michael; Nielsen, John; Dahl, Otto
SOURCE:	PCT Int. Appl., 34 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9705156	A1	19970213	WO 1996-DK330		19960726
W: AL, AM, AT, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ					
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT					
AU 9665140	A	19970226	AU 1996-65140		19960726
PRIORITY APPLN. INFO.:			DK 1995-863	A	19950727
			WO 1996-DK330	W	19960726

OTHER SOURCE(S): MARPAT 126:238622

GI



I

AB Functionalized achiral linker reagents, e.g. I [n = 1-3; Z = bond, C1-C10 chain optionally interrupted by 1-5 heteroatoms; R1 = H-phosphonate, phosphoramidite; R2 = amino protecting groups, e.g., PhCH2O2C, Me3CO2C, 9-fluorenylmethoxycarbonyl, allyloxycarbonyl, F3CCO, phthaloyl and reporter groups, e.g., fluorescein, dansyl, biotin, digoxigenin, N-oxyl-4,4-dimethyloxazolidine, N-oxyl-2,2,5,5-tetramethylpyrrolidine, texas red, tetramethylrhodamine, etc.; R3 = H, hydroxy protecting group, e.g., 4,4'-dimethoxytrityl, 9-fluorenylmethoxycarbonyl, etc.] were prepared and used to incorporate multiple primary amino groups or reporter groups into oligodeoxyribonucleotides following the phosphoramidite methodol. It is possible to substitute any deoxyribonucleotide, deoxynucleotide, or nucleotide with the linker in conventional phosphoramidite or H-phosphonate DNA syntheses. Thus, the bis(hydroxymethyl)benzylamine I (Z = CH2; R1 = H; R2 = 9-fluorenylmethylcarbonyl; R3 = 4,4'-dimethoxytrityl; n = 1) was prepared from 5-nitroisophthalic acid in seven steps. Application of this reagent in standard solid-support phosphoramidite oligodeoxyribonucleotide preparation methodol. gave, e.g., 5'-GTAGATCACT-P(O)(OH)OCH2-X-CH2OH-3' [X = 1,3-(5-H2NCH2)C6H3] with 99.5% coupling efficiency.

L10 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:155067 CAPLUS
DOCUMENT NUMBER: 126:207193
TITLE: Synthesis of Cobalamin Dimers Using Isophthalate Crosslinking of Corrin Ring Carboxylates and Evaluation of Their Binding to Transcobalamin. 2
AUTHOR(S): Pathare, Pradip M.; Wilbur, D. Scott; Hamlin, Donald K.; Heusser, Shannon; Quadros, Edward V.; McLoughlin, Patricia; Morgan, A. Charles
CORPORATE SOURCE: Department of Radiation Oncology, University of Washington, Seattle, WA, 98195, USA
SOURCE: Bioconjugate Chemistry (1997), 8(2), 161-172
CODEN: BCCHES; ISSN: 1043-1802
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Several cobalamin (Cbl) dimers have been prepared for evaluation as potential antiproliferative agents in the treatment of AIDS-related lymphoma. The Cbl dimers were synthesized by crosslinking Cbl carboxylates, produced by acid hydrolysis of the b-, d-, and e-propionamide side chains of cyanocobalamin (CN-Cbl), through an isophthalate mol. Linking mols. were used between the Cbl carboxylates and the isophthalate moiety. The linkers were incorporated to provide a distance between the two Cbl mols. such that the dimeric Cbls might bind two mols. of transcobalamin II (TCII), the Cbl transport protein in plasma. Initially, the linking moiety used was 1,12-diaminododecane, but the resulting dimers had low aqueous solubility To improve the solubility of the dimers, 4,7,10-trioxa-1,13-tridecanediamine was employed as the linking moiety. This improved the water solubility of the dimers considerably, while retaining the distance between the Cbl mols. at 41-42 Å (fully extended). To introduce addnl. substitution on Cbl dimers, 5-aminoisophthalic acid was used as the crosslinking reagent. P-Iodobenzoyl and p-(tri-n-butylstannyl)benzoyl conjugates of 5-aminoisophthalate were synthesized and used to prepare Cbl dimers. The stannylbenzoyl-conjugated Cbl dimers were prepared as precursors to be used in radioiodination reactions, and the iodobenzoyl-conjugated Cbl dimers were prepared as HPLC stds. for the radioiodinated product. Attempts to iodinate/radioiodinate the stannylbenzoyl Cbl dimers were unsuccessful. Although an explanation for this is not readily apparent, the failure to react may be due to the lipophilicity of the linker used and the steric environment of the two Cbl moieties. A biotinylated derivative of 5-aminoisophthalate was also synthesized and used to prepare

biotinylated-Cbl dimers. In a competitive rhTCII binding assay with [57Co]CN-Cbl, Cbl dimers containing the lipophilic diaminododecane linking moiety had decreased binding avidities compared to those of Cbl monomers substituted at the same corrin ring carboxylate. However, Cbl dimers containing the water-solubilizing trioxadiamine linker appeared to have avidities similar to those of the Cbl monomers.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:225167 CAPLUS
DOCUMENT NUMBER: 114:225167
TITLE: Method of assaying substances and immunoassay element employing β-D-galactosidase
INVENTOR(S): Onishi, Akira; Kawakatsu, Satoshi; Ito, Tsukasa; Takahashi, Takenori; Fukaya, Michie
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Eur. Pat. Appl., 61 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 328106	A2	19890816	EP 1989-102245		19890209
EP 328106	A3	19901219			
R: DE, GB					
JP 01308966	A	19891213	JP 1989-31530		19890209
JP 01308967	A	19891213	JP 1989-31531		19890209
PRIORITY APPLN. INFO.:			JP 1988-29632	A	19880209
			JP 1988-29633	A	19880209

OTHER SOURCE(S): MARPAT 114:225167

AB Disclosed is an assay element and a method of assaying a target substance in a fluid sample. In this method, a) the target substance; b) a substance which specifically binds to the target substance, to which a biol. active substance which does not bind to the target substance is attached, or to which a substance which specifically binds to a biol. active substance which does not bind to the target substance is attached; c) a labeled substance which is the target substance or an analog thereof labeled with β-D-galactosidase, or which is a substance which specifically binds to the target substance, labeled with β-D-galactosidase; d) a substance which specifically binds to the biol. active substance and which does not bind to the target substance, or the biol. active substance, which is fixed to a carrier, which carrier exists in a porous reaction layer of an assay element; and e) a substance which specifically binds to β-D-galactosidase and which changes a signal originated from β-D-galactosidase, which is fixed to said carrier or another carrier which exists in a porous reaction layer of an assay element, are reacted, and the change of the signal from β-D-galactosidase is measured. Human IgG was determined by mixing the sample with bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane, β-D-galactosidase-labeled human IgG, and biotin-bound anti-human IgG antibody and applying the mixture to an immunoassay element comprising a PET film coated with 1) a solution containing gelatin, Triton X-100, 1,2-bis(vinylsulfonyl)ethane, and H2O; 2) a solution containing p-aminophenylmercuric acetate-bound Avicel (microcryst. cellulose), Triton X-100, polyvinylpyrrolidone, 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside, 3,3'-(4,4'-biphenylene)-bis(2,5-diphenyl-2H-tetrazolium chloride), and n-BuOH; 3) a solution containing avidin-bound Avicel containing bovine serum albumin and sucrose, Triton X-100, polyvinylpyrrolidone, and n-BuOH;

and 4) a solution containing cellulose powder D, Triton X-100, polyvinylpyrrolidone, and n-BuOH. The element was incubated at 37° for 10 min and then the reflection d. at 546 nm was measured from the side of the support layer.

=> d L12 1-10 ibib abs

L12 ANSWER 1 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:33958 CAPLUS
DOCUMENT NUMBER: 146:135595
TITLE: Compositions and methods for providing a graded response in a protein, and therapeutic and other uses
INVENTOR(S): Graves, Barbara J.; Pufall, Miles; Lee, Gregory M.; Mcintosh, Lawrence
PATENT ASSIGNEE(S): University of Utah Research Foundation, USA; University of British Columbia
SOURCE: PCT Int. Appl., 29pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007005867	A2	20070111	WO 2006-US26038	20060630

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-695951P P 20050630
AB The invention discloses compns. and methods which are of use for the graded control of proteins through modification of the post-translational state of the proteins. In particular, the methods provide for the subtle and gradual control of protein levels in direct contrast to the traditional theory of protein levels merely being "on" at one consistent level or completely "off." The ability to modify protein levels may be useful in the production of a variety of cell types, including whole animals or plants, or for therapeutic or laboratory research purposes. Addnl., the methods of the invention may be used to produce or inhibit particular proteins in patients suffering from diseases caused by the complete lack of a particular protein or an incorrect level of a protein.

L12 ANSWER 2 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2007:79558 CAPLUS
TITLE: Trifunctional norrisolide probes for the study of Golgi vesiculation
AUTHOR(S): Guizzunti, Gianni; Brady, Thomas P.; Malhotra, Vivek; Theodorakis, Emmanuel A.
CORPORATE SOURCE: Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093-0358, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(2), 320-325
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Inspired by the effect of norrisolide on the Golgi complex, we synthesized norrisolide probes that contain: the perhydroindane core of the parent natural product for Golgi localization, a crosslinking unit (aryl azide or epoxide) for covalent binding to the target, and a tag (biotin or iodine) for subsequent target purification We found that biotin -containing probes 14, 20 and 24 induced inefficient Golgi vesiculation. However, the iodinated probe 25 induced extensive and irreversible Golgi fragmentation. This probe can be used for the isolation of the cellular target of norrisolide.
REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1124832 CAPLUS
DOCUMENT NUMBER: 145:443804
TITLE: Amphiphilic polymers and methods of use thereof
INVENTOR(S): Colton, Clark K.; Watterson, Arthur; Kumar, Rajesh; Parmar, Virinder S.; Fisher, Robert; Kumar, Jayant
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA
SOURCE: PCT Int. Appl., 127pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2006113666	A2	20061026	WO 2006-US14483		20060417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
US 2006269479	A1	20061130	US 2006-405012		20060417
PRIORITY APPLN. INFO.:			US 2005-672533P	P	20050419
			US 2005-672856P	P	20050420
			US 2005-732633P	P	20051103

AB The present invention relates to amphiphilic polymers, and micelles and compns. comprising the same, and their use in a variety of biol. settings, including imaging, targeting drugs, or a combination thereof for diagnostic and therapeutic purposes. A PEG oligomer, for example, is polymerized with a trifunctional linking mol. (di-Me 5-hydroxyisophthalate) using lipase B which leaves the phenolic hydroxy group available for further chemical reaction. The PEG may be further modified with perfluorododecanol, fluorescent probes, targeting peptides, etc. The resulting multimodal agent is used for imaging tumors, such as human epithelial cell adenocarcinomas which overexpress uMUC-1 antigen.

L12 ANSWER 4 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1228654 CAPLUS
DOCUMENT NUMBER: 145:501841
TITLE: Tri-functional nanospheres formed from mesoporous polymer, magnetic material, fluorescent dye and a

biomaterial coupled to the polymer
INVENTOR(S): Pang, Dai-Wen; Xie, Hai-Yan; Wang, Guo-Ping; Zhang, Zhi-Ling; Song, Er-Qun; Shi, Yun-Bo
PATENT ASSIGNEE(S): Wuhan University, Peop. Rep. China; The Government of the U.S as Represented by the Secretary of the Dept of Health and Human Services
SOURCE: U.S. Pat. Appl. Publ., 18pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006263906	A1	20061123	US 2005-135380		20050524
CN 1869692	A	20061129	CN 2005-10079227		20050523
PRIORITY APPLN. INFO.:			CN 2005-10079227	A	20050523

AB Trifunctional nanoparticles have excellent fluorescence, magnetism, and cell recognition, which can be easily manipulated, tracked, and conveniently used to capture target cells. The surface-immobilized mols. of the TFNs might be optionally changed on demand for the purposes of bioanal., biomedical imaging, diagnosis, and the combinatorial screening of drugs. The nanoparticle is formed from a mesoporous polymer; a magnetic material adhering to the mesoporous polymer; a fluorescent dye adhering to the mesoporous polymer; and a biomaterial coupled to the mesoporous polymer, where the mesoporous polymer has been treated with hydrazine, and the biomaterial has been treated with an oxidizing agent.

L12 ANSWER 5 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:75114 CAPLUS
DOCUMENT NUMBER: 144:145994
TITLE: Planar optical waveguide based sandwich assay sensors and processes for the detection of biological targets including protein markers, pathogens and cellular debris
INVENTOR(S): Martinez, Jennifer S.; Swanson, Basil I.; Grace, Karen M.; Grace, Wyane K.; Shreve, Andrew P.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006019244	A1	20060126	US 2005-172246		20050629
US 2006019321	A1	20060126	US 2005-172244		20050629
PRIORITY APPLN. INFO.:			US 2004-583911P	P	20040629

AB An assay element is described including recognition ligands bound to a film on a single mode planar optical waveguide, the film from the group of a membrane, a polymerized bilayer membrane, and a self-assembled monolayer containing polyethylene glycol or polypropylene glycol groups therein and an assay process for detecting the presence of a biol. target is described including injecting a biol. target-containing sample into a sensor cell including the assay element, with the recognition ligands adapted for binding to selected biol. targets, maintaining the sample within the sensor cell for time sufficient for binding to occur between selected biol. targets within the sample and the recognition ligands, injecting a solution including a reporter ligand into the sensor cell; and, interrogating the sample within the sensor cell with excitation light from the waveguide, the excitation light provided by an evanescent field of the

single mode penetrating into the biol. target-containing sample to a distance of less than about 200 nm from the waveguide thereby exciting the fluorescent-label in any bound reporter ligand within a distance of less than about 200 nm from the waveguide and resulting in a detectable signal. Biotinylated capture antibodies were coupled through avidin/ streptavidin to biotinylated phospholipid bilayers composed of 1 % to 3 % biotin-phosphoethanolamine in a matrix of DOPC (1,2-Dioleoyl-sn-Glycero-3-Phosphocholine) and attached to the surface of planar optical waveguides. Alexa Fluor 532- or 647-labeled monoclonal antibodies specific for B. anthracis were used as reporter ligands. The performance of the immunoassay was evaluated by monitoring the response of the waveguide apparatus to varying concns. of Bacillus anthracis protective antigen.

L12 ANSWER 6 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1242827 CAPLUS
DOCUMENT NUMBER: 146:28352
TITLE: Water-soluble multi-biotin-containing compounds
INVENTOR(S): Wilbur, D. Scott; Pathare, Pradip M.; Hamlin, Donald K.; Wan, Feng
PATENT ASSIGNEE(S): University of Washington, USA
SOURCE: U.S., 98pp., Cont.-in-part of U.S. Ser. No. 324,267, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7141676	B1	20061128	US 2002-261040	20020930
US 2006228325	A1	20061012	US 2006-435963	20060517

PRIORITY APPLN. INFO.:

US 1996-11321P	P	19960208
US 1997-798413	B2	19970207
US 1999-324267	B2	19990602
US 2002-261040	A3	20020930

AB Water-soluble discrete multi-biotin-containing compds. with ≥ 3 biotin moieties are disclosed. The water-soluble biotin -containing compds. may addnl. comprise ≥1 moieties that confer resistance to cleavage by biotinidase or that is cleavable in vitro or in vivo. The discrete multi-biotin-containing compds. may include a reactive moiety that provides a site for reaction with yet another moiety, such as a targeting, diagnostic or therapeutic functional moiety. Biotinylation reagents comprising water-soluble linker moieties are also disclosed and may addnl. comprise a biotinidase protective group. Methods for amplifying the number of sites for binding biotin-binding proteins at a selected target using multi-biotin compds. also are disclosed.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2006:367724 CAPLUS
DOCUMENT NUMBER: 145:6459
TITLE: Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheral monocytes
AUTHOR(S): Laumonnier, Yves; Syrovets, Tatiana; Burysek, Ladislav; Simmet, Thomas
CORPORATE SOURCE: Department of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Germany
SOURCE: Blood (2006), 107(8), 3342-3349

CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We have previously demonstrated that plasmin acts as a potent proinflammatory activator of human peripheral monocytes. Here we identify the annexin A2 heterotetramer, composed of annexin A2 and S100A10, as a receptor for the plasmin-induced signaling in human monocytes. Monocytes express the annexin A2 heterotetramer on the cell surface as shown by flow cytometry, fluorescence microscopy, and coimmunopptn. of biotinylated cell surface proteins. Binding of plasmin to annexin A2 and S100A10 on monocytes was verified by biotin transfer from plasmin labeled with a trifunctional crosslinker. Antibodies directed against annexin A2 or S100A10 inhibited the chemotaxis elicited by plasmin, but not that induced by fMLP. Further, down-regulation of annexin A2 or S100A10 in monocytes by antisense oligodeoxynucleotides impaired the chemotactic response to plasmin, but not that to fMLP. Antisense oligodeoxynucleotides similarly decreased the TNF-α release by plasmin-stimulated, but not by LPS-stimulated, monocytes. At the mol. level, stimulation with plasmin, but not with catalytically inactivated plasmin, induced cleavage of annexin A2 and dissociation of the heterotetramer complex. Substitution of lysine to alanine in position 27 abolished the cleavage of recombinant annexin A2 in vitro. Together, these data identify the annexin A2 heterotetramer as a signaling receptor activated by plasmin via proteolysis.
REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2006:453922 CAPLUS
DOCUMENT NUMBER: 145:117200
TITLE: Design and synthesis of a biotin-tagged photoaffinity probe of paeoniflorin
AUTHOR(S): Qiu, Wen-Wei; Xu, Jie; Liu, Da-Zhi; Li, Jing-Ya; Ye, Yang; Zhu, Xing-Zu; Li, Jia; Nan, Fa-Jun
CORPORATE SOURCE: Chinese National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Shanghai, 201203, Peop. Rep. China
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(12), 3306-3309
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:117200
AB A trifunctional probe (binding element-photoreactive group-affinity tag) of natural product paeoniflorin was designed and synthesized based on the previous primary structure-activity relationship. This new probe is a potential tool for labeling, purification, and identification of the target proteins.
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2006:756884 CAPLUS
DOCUMENT NUMBER: 145:331093
TITLE: Identifying an interaction site between MutH and the C-terminal domain of MutL by crosslinking, affinity purification, chemical coding and mass spectrometry
AUTHOR(S): Ahrends, Robert; Kosinski, Jan; Kirsch, Dieter; Manelyte, Laura; Giron-Monzon, Luis; Hummerich, Lars; Schulz, Oliver; Spengler, Bernhard; Friedhoff, Peter
CORPORATE SOURCE: Institut fuer Biochemie (FB 08), Justus-Liebig-

Universitaet, Giessen, D-35392, Germany
SOURCE: Nucleic Acids Research (2006), 34(10), 3169-3180
CODEN: NARHAD; ISSN: 0305-1048
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB To investigate protein-protein interaction sites in the DNA mismatch repair system the authors developed a crosslinking/mass spectrometry technique employing a com. available trifunctional crosslinker with a thiol-specific methanethiosulfonate group, a photoactivatable benzophenone moiety and a biotin affinity tag. The XACM approach combines photocrosslinking (X), in-solution digestion of the crosslinked mixts., affinity purification via the biotin handle (A), chemical coding of the crosslinked products (C) followed by MALDI-TOF mass spectrometry (M). The authors illustrate the feasibility of the method using a single-cysteine variant of the homodimeric DNA mismatch repair protein MutL. Moreover, the authors successfully applied this method to identify the photocrosslink formed between the single-cysteine MutH variant A223C, labeled with the trifunctional crosslinker in the C-terminal helix and its activator protein MutL. The identified crosslinked MutL-peptide maps to a conserved surface patch of the MutL C-terminal dimerization domain. These observations are substantiated by addnl. mutational and chemical crosslinking studies. The authors' results shed light on the potential structures of the MutL holoenzyme and the MutH-MutL-DNA complex.
REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 2006:284754 CAPLUS
DOCUMENT NUMBER: 144:484013
TITLE: Design and synthesis of novel photoaffinity reagents for labeling VEGF receptor tyrosine kinases
AUTHOR(S): Han, Sun-Young; Choi, Seo Hyun; Kim, Myung Hee; Lee, Woo Ghil; Kim, Seong Hwan; Min, Yong Ki; Kim, Bum Tae
CORPORATE SOURCE: Bio-Organic Science Division, Korea Research Institute of Chemical Technology, Daejeon, 305-600, S. Korea
SOURCE: Tetrahedron Letters (2006), 47(17), 2915-2919
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:484013
AB Novel biotin-tagged photoaffinity probes based on a trifunctional tertiary amine scaffold were synthesized and evaluated as vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors. Probes inhibit VEGF induced proliferation in HUVE cells, with IC50 values of 29.7, 33.3, and 37.7 μM, resp. Moreover, we identified the interaction of with VEGFR-2 in photoaffinity labeling experiment using HUVE cells.
REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s L12 and toxin
L14 8 L12 AND TOXIN

=> d L14 1-8 ibib abs

L14 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1124832 CAPLUS
DOCUMENT NUMBER: 145:443804
TITLE: Amphiphilic polymers and methods of use thereof
INVENTOR(S): Colton, Clark K.; Watterson, Arthur; Kumar, Rajesh;

Parmar, Virinder S.; Fisher, Robert; Kumar, Jayant
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA
SOURCE: PCT Int. Appl., 127pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006113666	A2	20061026	WO 2006-US14483	20060417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006269479	A1	20061130	US 2006-405012	20060417

PRIORITY APPLN. INFO.:
US 2005-672533P P 20050419
US 2005-672856P P 20050420
US 2005-732633P P 20051103

AB The present invention relates to amphiphilic polymers, and micelles and compns. comprising the same, and their use in a variety of biol. settings, including imaging, targeting drugs, or a combination thereof for diagnostic and therapeutic purposes. A PEG oligomer, for example, is polymerized with a trifunctional linking mol. (di-Me 5-hydroxyisophthalate) using lipase B which leaves the phenolic hydroxy group available for further chemical reaction. The PEG may be further modified with perfluorododecanol, fluorescent probes, targeting peptides, etc. The resulting multimodal agent is used for imaging tumors, such as human epithelial cell adenocarcinomas which overexpress uMUC-1 antigen.

L14 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:75114 CAPLUS
DOCUMENT NUMBER: 144:145994
TITLE: Planar optical waveguide based sandwich assay sensors and processes for the detection of biological targets including protein markers, pathogens and cellular debris
INVENTOR(S): Martinez, Jennifer S.; Swanson, Basil I.; Grace, Karen M.; Grace, Wyane K.; Shreve, Andrew P.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006019244	A1	20060126	US 2005-172246	20050629
US 2006019321	A1	20060126	US 2005-172244	20050629

PRIORITY APPLN. INFO.:
US 2004-583911P P 20040629

AB An assay element is described including recognition ligands bound to a film on a single mode planar optical waveguide, the film from the group of a membrane, a polymerized bilayer membrane, and a self-assembled monolayer

containing polyethylene glycol or polypropylene glycol groups therein and an assay process for detecting the presence of a biol. target is described including injecting a biol. target-containing sample into a sensor cell including the assay element, with the recognition ligands adapted for binding to selected biol. targets, maintaining the sample within the sensor cell for time sufficient for binding to occur between selected biol. targets within the sample and the recognition ligands, injecting a solution including a reporter ligand into the sensor cell; and, interrogating the sample within the sensor cell with excitation light from the waveguide, the excitation light provided by an evanescent field of the single mode penetrating into the biol. target-containing sample to a distance of less than about 200 nm from the waveguide thereby exciting the fluorescent-label in any bound reporter ligand within a distance of less than about 200 nm from the waveguide and resulting in a detectable signal. Biotinylated capture antibodies were coupled through avidin/ streptavidin to biotinylated phospholipid bilayers composed of 1 % to 3 % biotin-phosphoethanolamine in a matrix of DOPC (1,2-Dioleoylsn-Glycero-3-Phosphocholine) and attached to the surface of planar optical waveguides. Alexa Fluor 532- or 647-labeled monoclonal antibodies specific for B. anthracis were used as reporter ligands. The performance of the immunoassay was evaluated by monitoring the response of the waveguide apparatus to varying concns. of Bacillus anthracis protective antigen.

L14 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:493522 CAPLUS
DOCUMENT NUMBER: 143:32224
TITLE: Immunoconjugates for targeting of ERB antigens
INVENTOR(S): Sandberg, Bengt E. B.; Nilsson, Rune
PATENT ASSIGNEE(S): Mitra Medical AB, Swed.
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051424	A1	20050609	WO 2004-SE1753	20041126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004292933	A1	20050609	AU 2004-292933	20041126
CA 2547435	A1	20050609	CA 2004-2547435	20041126
EP 1708750	A1	20061011	EP 2004-800410	20041126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1905900	A	20070131	CN 2004-80041118	20041126
NO 2006002410	A	20060824	NO 2006-2410	20060526
PRIORITY APPLN. INFO.:			SE 2003-3229 A	20031128
			US 2003-525703P P	20031128
			WO 2004-SE1753 W	20041126

AB A conjugate comprising a) a trifunctional crosslinking moiety, to which is coupled b) an affinity ligand via a linker 1, c) a cytotoxic agent, optionally via a linker 2, and d) an anti Erb antibody or variants

thereof having the ability to bind to Erb antigens expressed on mammalian tumor surfaces with an affinity-binding constant of at least 5x106M-1, wherein the affinity ligand is biotin, or a biotin derivative having essentially the same binding function to avidin or streptavidin as biotin, wherein stability towards enzymic cleavage of the biotinamide bond has been introduced in linker 1.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:60754 CAPLUS
Correction of: 2004:1036571

DOCUMENT NUMBER: 142:233342
Correction of: 142:16836

TITLE: Sequences of human schizophrenia related genes and use for diagnosis, prognosis and therapy

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 156 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 32

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2007031841	A1	20070208	US 2003-601518	20030620
US 2006134635	A1	20060622	US 2004-802875	20040312
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2005208519	A1	20050922	US 2004-989191	20041115
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2001-271955P	P 20010228
			US 2001-275017P	P 20010312
			US 2001-305340P	P 20010713
			US 2002-85783	A2 20020228
			US 2004-812731	A2 20040330
			WO 2004-US20836	A2 20040621

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L14 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:531387 CAPLUS

DOCUMENT NUMBER: 141:94296

TITLE: Anti-lymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
INVENTOR(S): Sandberg, Bengt; Nilsson, Rune
PATENT ASSIGNEE(S): Mitra Medical Technology Ab, Swed.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054615	A1	20040701	WO 2003-SE1949	20031212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509103	A1	20040701	CA 2003-2509103	20031212
AU 2003287131	A1	20040709	AU 2003-287131	20031212
EP 1569690	A1	20050907	EP 2003-781200	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016599	A	20051004	BR 2003-16599	20031212
CN 1738645	A	20060222	CN 2003-80108743	20031212
JP 2006511532	T	20060406	JP 2004-560221	20031212
NO 2005002842	A	20050912	NO 2005-2842	20050613
US 2006222588	A1	20061005	US 2006-538669	20060309

PRIORITY APPLN. INFO.:	SE 2002-3731	A	20021213
	US 2002-433012P	P	20021213
	WO 2003-SE1949	W	20031212

AB Disclosed are a medical agent comprising a reagent conjugated to an anti-lymphoma antibody, as well as a kit containing the medical agent, use of the medical agent, and a method for the treatment of lymphoma. The reagent may comprise an effector, e.g. an antitumor agent or a diagnostic marker, and an affinity ligand enabling extracorporeal clearance of the agent. The three components are bound by a trifunctional linker. For example, rituximab (monoclonal antibody) was treated with 3-(13'-thioureabenzylDOTA)trioxadiamine-1-(13''-biotin -Asp-OH)trioxadiamine-5-isothiocyanato-aminoisophthalate and mixed with 111InCl3 and DTPA to obtain a conjugate.
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:923565 CAPLUS
DOCUMENT NUMBER: 136:42919
TITLE: Biotin derivatives for an extracorporeal device
INVENTOR(S): Sandberg, Bengt; Wilbur, Scott; Nilsson, Rune
PATENT ASSIGNEE(S): Mitra Medical Technology AB, Swed.; University of Washington
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095857	A2	20011220	WO 2001-SE1374	20010618
WO 2001095857	A3	20020328		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002159994	A1	20021031	US 2001-881213	20010615
CA 2412495	A1	20011220	CA 2001-2412495	20010618
AU 2001074761	A5	20011224	AU 2001-74761	20010618
EP 1289563	A2	20030312	EP 2001-941404	20010618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011726	A	20030527	BR 2001-11726	20010618
JP 2004503299	T	20040205	JP 2002-510039	20010618
HU 200401953	A2	20041228	HU 2004-1953	20010618
RU 2279896	C2	20060720	RU 2003-101060	20010618
NO 2002005931	A	20030214	NO 2002-5931	20021211
US 2004052784	A1	20040318	US 2003-311150	20030423
PRIORITY APPLN. INFO.:			SE 2000-2287 A	20000616
			US 2000-216625P P	20000707
			WO 2001-SE1374 W	20010618

AB A method for the conditioning of an extracorporeal device is described, as well as a method for extracorporeal extraction of toxic material from mammalian body fluids in connection with diagnosis or treatment of a mammalian condition or disease. The methods comprise (i) a solution containing a reagent comprising biotin moieties, such as natural biotin or its derivs., and a toxin-binding moiety, (ii) linkers and a trifunctional crosslinking moiety, and (ii) an extracorporeal device comprising said reagent. For example, a dibiotin compound, 1-isothiocyanato-3,5-bis-(13'-biotinamidyl-4',7',10'-trioxatridecanamidyl)-aminoisophthalate was prepared and conjugated with a toxin-binding mol., i.e., monoclonal antibody 53-6A2. A dibiotin-toxin -binding conjugate was used for conditioning of an avidin-agarose column suitable for removal of toxins from blood.

L14 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:35037 CAPLUS
DOCUMENT NUMBER: 132:90367
TITLE: Trifunctional reagent for conjugation to a biomolecule for use in diagnosis and therapy
INVENTOR(S): Wilbur, D. Scott; Sandberg, Bengt E. B.
PATENT ASSIGNEE(S): University of Washington, USA; Mitra Medical Technology AB
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002051	A1	20000113	WO 1999-SE1241	19990707
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,				

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2000002050	A1	20000113	WO 1998-SE1345	19980707
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2336739	A1	20000113	CA 1999-2336739	19990707
AU 9950767	A	20000124	AU 1999-50767	19990707
EP 1095274	A1	20010502	EP 1999-935251	19990707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002519440	T	20020702	JP 2000-558395	19990707
US 2001023288	A1	20010920	US 2000-750280	20001229
NO 2001000021	A	20010307	NO 2001-21	20010103
PRIORITY APPLN. INFO.:			WO 1998-SE1345 A	19980707
			WO 1999-SE1241 W	19990707

AB A reagent for conjugation to a biomol. for diagnosis and treatment of human and animal conditions and diseases is described, wherein the reagent is a single mol. with at least three functional parts and a) wherein a trifunctional crosslinking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with another mol. having affinity for said ligand; to c) an effector agent, optionally via a linker 2, said effector agent exerting its effects on cells, tissues and/or humorous mols. in vivo or ex vivo; and to d) a biomol. reactive moiety, optionally via a linker 3, said moiety being capable of forming a bond between the reagent and the biomol. The affinity ligand is especially biotin or a biotin derivative The effector agent is a toxin, an enzyme capable of converting a prodrug to an active drug, an immunosuppressant, an immunostimulant, or a radionuclide-binding agent, with or without the radionuclide.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:35036 CAPLUS
DOCUMENT NUMBER: 132:90366
TITLE: Trifunctional reagent for conjugation to a biomolecule for use in diagnosis and therapy
INVENTOR(S): Wilbur, D. Scott; Sandberg, Bengt E. B.
PATENT ASSIGNEE(S): University of Washington, USA; Mitra Medical Technology AB
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002050	A1	20000113	WO 1998-SE1345	19980707
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,				

TT, UA, UG, US, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9883663	A	20000124	AU 1998-83663	19980707
CA 2336739	A1	20000113	CA 1999-2336739	19990707
WO 2000002051	A1	20000113	WO 1999-SE1241	19990707

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9950767	A	20000124	AU 1999-50767	19990707
EP 1095274	A1	20010502	EP 1999-935251	19990707

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2002519440	T	20020702	JP 2000-558395	19990707
NO 2001000021	A	20010307	NO 2001-21	20010103
US 2005271673	A1	20051208	US 2005-190955	20050728

PRIORITY APPLN. INFO.:

WO 1998-SE1345	A	19980707
WO 1999-SE1241	W	19990707
US 2000-519998	B1	20000306

AB A reagent for conjugation to a biomol. for diagnosis and treatment of human and animal conditions and diseases is described, wherein the reagent is a single mol. with at least three functional parts and a) wherein a trifunctional crosslinking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with another mol. having affinity for said ligand; to c) an effector agent, optionally via a linker 2, said effector agent exerting its effects on cells, tissues and/or humorous mols. in vivo or ex vivo; and to d) a biomol. reactive moiety, optionally via a linker 3, said moiety being capable of forming a bond between the reagent and the biomol. The affinity ligand is especially biotin or a biotin derivative The effector agent is a toxin, an enzyme capable of converting a prodrug to an active drug, an immunosuppressant, an immunostimulant, or a radionuclide-binding agent, with or without the radionuclide.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s extracorporeal
L15      72238 EXTRACORPOREAL

=> s L12 and L15
L16          6 L12 AND L15

=> d 1-6 L16 ibib abs

L16  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2005:1019038  CAPLUS
DOCUMENT NUMBER:         144:145495
TITLE:                   A novel platform for radioimmunotherapy:
                         extracorporeal depletion of biotinylated and
                         90Y-labeled rituximab in patients with refractory
                         B-cell lymphoma
AUTHOR(S):               Linden, Ola; Kurkus, Jan; Garkavij, Michael;
                         Cavallin-Staahl, Eva; Ljungberg, Michael; Nilsson,
                         Rune; Ohlsson, Tomas; Sandberg, Bengt; Strand,
                         Sven-Erik; Tennvall, Jan
CORPORATE SOURCE:        Department of Oncology, Lund University, Lund, Swed.
SOURCE:                  Cancer Biotherapy & Radiopharmaceuticals (2005),
```

20(4), 457-466
CODEN: CBRAFJ; ISSN: 1084-9785
PUBLISHER: Mary Ann Liebert, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Radioimmunotherapy is limited by the absorbed dose to radiosensitive organs. Removal of circulating radiolabeled MAbs after tumor tissue has been optimally targeted and should permit the administration of higher radioactivity to patients, resulting in a higher absorbed tumor dose. A novel "extracorporeal affinity adsorption treatment" (ECAT) device (MitraDep) was tested, with which biotinylated and radiolabeled MAbs can be removed from the circulation by passing whole blood over a filter coated with avidin. The antibodies were simultaneously radiolabeled and biotinylated using a trifunctional moiety comprising DOTA and biotin. Eight patients-all but 1 of whom with aggressive or mantle cell B-cell lymphoma-who had failed to respond to standard therapies received infusions of 250 mg/m2 cold rituximab and 150 MBq 111In-rituximab-biotin for immunoscintigraphy. A week later, the patients were treated with another 250 mg/m2 rituximab followed by 111In/-90Y-rituximab-biotin (11 or 15 90Y MBq/kg). ECAT was performed 48 h later. All 8 patients receiving 111In-rituximab-biotin showed tumor uptake. Seven patients received radioimmunotherapy and subsequent ECAT. The mean depletion of 90Y-rituximab-biotin in whole blood after ECAT was 96%, in the whole body 49%, in the lungs 62%, and in the liver and kidneys 40%. No effects on patients' vital signs and no adverse effects on hematol. or coagulation parameters was observed during the ECAT procedure. A dose-escalation study is initiated.
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:531387 CAPLUS
DOCUMENT NUMBER: 141:94296
TITLE: Anti-lymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
INVENTOR(S): Sandberg, Bengt; Nilsson, Rune
PATENT ASSIGNEE(S): Mitra Medical Technology Ab, Swed.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054615	A1	20040701	WO 2003-SE1949	20031212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509103	A1	20040701	CA 2003-2509103	20031212
AU 2003287131	A1	20040709	AU 2003-287131	20031212
EP 1569690	A1	20050907	EP 2003-781200	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

BR 2003016599	A	20051004	BR 2003-16599		20031212
CN 1738645	A	20060222	CN 2003-80108743		20031212
JP 2006511532	T	20060406	JP 2004-560221		20031212
NO 2005002842	A	20050912	NO 2005-2842		20050613
US 2006222588	A1	20061005	US 2006-538669		20060309
PRIORITY APPLN. INFO.:			SE 2002-3731	A	20021213
			US 2002-433012P	P	20021213
			WO 2003-SE1949	W	20031212

AB Disclosed are a medical agent comprising a reagent conjugated to an anti-lymphoma antibody, as well as a kit containing the medical agent, use of the medical agent, and a method for the treatment of lymphoma. The reagent may comprise an effector, e.g. an antitumor agent or a diagnostic marker, and an affinity ligand enabling extracorporeal clearance of the agent. The three components are bound by a trifunctional linker. For example, rituximab (monoclonal antibody) was treated with 3-(13'-thioureabenzylDOTA)trioxadiamine-1-(13''-biotin -Asp-OH)trioxadiamine-5-isothiocyanato-aminoisophthalate and mixed with 111InCl3 and DTPA to obtain a conjugate.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:523951 CAPLUS

DOCUMENT NUMBER: 137:228855

TITLE: Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies

AUTHOR(S): Wilbur, D. Scott; Chyan, Ming-Kuan; Hamlin, Donald K.; Kegley, Brian B.; Nilsson, Rune; Sandberg, Bengt E. B.; Brechbiel, Martin

CORPORATE SOURCE: Department of Radiation Oncology, University of Washington, Seattle, WA, 98195, USA

SOURCE: Bioconjugate Chemistry (2002), 13(5), 1079-1092 CODEN: BCCHES; ISSN: 1043-1802

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A method of removing radiolabeled monoclonal antibodies (mAbs) from blood using a device external to the body, termed extracorporeal affinity-adsorption (EAA), is being evaluated as a means of decreasing irradiation of noncancerous tissues in therapy protocols. The EAA device uses an avidin column to capture biotinylated-radiolabeled mAbs from circulated blood. In this investigation, three trifunctional reagents have been developed to minimize the potential deleterious effect on antigen binding brought about by the combination of radiolabeling and biotinylation of mAbs required in the EAA approach. The studies focused on radiolabeling with 111In and 90Y, so the chelates CHX-A''-DTPA and DOTA, which form stable attachments to these radionuclides, were incorporated in the trifunctional reagents. The first trifunctional reagent prepared did not incorporate a group to block the biotin cleaving enzyme biotinidase, but the two subsequent reagents coupled aspartic acid to the biotin carboxylate for that purpose. All three reagents used 4,7,10-trioxa-1,13-tridecanediamine as water-soluble spacers between an aminoisophthalate core and the biotin or chelation group. The mAb conjugates were radioiodinated to evaluate cell binding as a function of substitution. Radioiodination was used so that a direct comparison with unmodified mAb could be made. Evaluation of the number of conjugates per antibody vs. cell binding immunoreactivities indicated that minimizing the number of conjugates was best. Interestingly, a decrease of radioiodination yield as a function of the number of isothiocyanate containing conjugates per mAb was noted. The decreased yields were presumably due to the presence of thiourea

functionality formed in the conjugation reaction. Radiolabeling with 111In and 90Y was facile at room temperature for conjugates containing the CHX-A'', but elevated temperature (e.g., 45°) was required to obtain good yields with the DOTA chelate. Stability of 90Y labeled mAb in serum, and when challenged with 10 mM EDTA, was high. However, challenging the 90Y labeled mAb with 10 mM DTPA demonstrated high stability for the DOTA containing conjugate, but low stability for the CHX-A'' containing conjugate. Thus, the choice between these two chelating moieties might be made on requirements for facile and gentle labeling vs. very high in vivo stability. Application of the trifunctional biotinylation reagents to the blood clearance of labeled antibodies in EAA is under investigation. The new reagents may also be useful for other applications.

REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:923565 CAPLUS
DOCUMENT NUMBER: 136:42919
TITLE: Biotin derivatives for an extracorporeal device
INVENTOR(S): Sandberg, Bengt; Wilbur, Scott; Nilsson, Rune
PATENT ASSIGNEE(S): Mitra Medical Technology AB, Swed.; University of Washington
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095857	A2	20011220	WO 2001-SE1374	20010618
WO 2001095857	A3	20020328		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002159994	A1	20021031	US 2001-881213	20010615
CA 2412495	A1	20011220	CA 2001-2412495	20010618
AU 2001074761	A5	20011224	AU 2001-74761	20010618
EP 1289563	A2	20030312	EP 2001-941404	20010618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011726	A	20030527	BR 2001-11726	20010618
JP 2004503299	T	20040205	JP 2002-510039	20010618
HU 200401953	A2	20041228	HU 2004-1953	20010618
RU 2279896	C2	20060720	RU 2003-101060	20010618
NO 2002005931	A	20030214	NO 2002-5931	20021211
US 2004052784	A1	20040318	US 2003-311150	20030423

PRIORITY APPLN. INFO.:	SE 2000-2287	A	20000616
	US 2000-216625P	P	20000707
	WO 2001-SE1374	W	20010618

AB A method for the conditioning of an extracorporeal device is described, as well as a method for extracorporeal extraction of toxic material from mammalian body fluids in connection with diagnosis or treatment of a mammalian condition or disease. The methods comprise (i) a solution containing a reagent comprising biotin moieties, such as

natural biotin or its derivs., and a toxin-binding moiety, (ii) linkers and a trifunctional crosslinking moiety, and (ii) an extracorporeal device comprising said reagent. For example, a dibiotin compound, 1-isothiocyanato-3,5-bis-(13'-biotinamidyl-4',7',10'-trioxatridecanamidyl)-aminoisophthalate was prepared and conjugated with a toxin-binding mol., i.e., monoclonal antibody 53-6A2. A dibiotin-toxin-binding conjugate was used for conditioning of an avidin-agarose column suitable for removal of toxins from blood.

L16 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:35037 CAPLUS
DOCUMENT NUMBER: 132:90367
TITLE: Trifunctional reagent for conjugation to a biomolecule for use in diagnosis and therapy
INVENTOR(S): Wilbur, D. Scott; Sandberg, Bengt E. B.
PATENT ASSIGNEE(S): University of Washington, USA; Mitra Medical Technology AB
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002051	A1	20000113	WO 1999-SE1241	19990707
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2000002050	A1	20000113	WO 1998-SE1345	19980707
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2336739	A1	20000113	CA 1999-2336739	19990707
AU 9950767	A	20000124	AU 1999-50767	19990707
EP 1095274	A1	20010502	EP 1999-935251	19990707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002519440	T	20020702	JP 2000-558395	19990707
US 2001023288	A1	20010920	US 2000-750280	20001229
NO 2001000021	A	20010307	NO 2001-21	20010103

PRIORITY APPLN. INFO.:

WO 1998-SE1345	A	19980707
WO 1999-SE1241	W	19990707

AB A reagent for conjugation to a biomol. for diagnosis and treatment of human and animal conditions and diseases is described, wherein the reagent is a single mol. with at least three functional parts and a) wherein a trifunctional crosslinking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with another mol. having affinity for said ligand; to c) an effector agent, optionally via a linker 2, said effector agent exerting its effects on cells, tissues and/or humorous mols. in vivo or ex vivo; and to d) a biomol. reactive moiety, optionally via a linker 3, said moiety being capable of forming a bond between the reagent and the biomol. The

affinity ligand is especially biotin or a biotin derivative The effector agent is a toxin, an enzyme capable of converting a prodrug to an active drug, an immunosuppressant, an immunostimulant, or a radionuclide-binding agent, with or without the radionuclide.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:35036 CAPLUS
DOCUMENT NUMBER: 132:90366
TITLE: Trifunctional reagent for conjugation to a biomolecule for use in diagnosis and therapy
INVENTOR(S): Wilbur, D. Scott; Sandberg, Bengt E. B.
PATENT ASSIGNEE(S): University of Washington, USA; Mitra Medical Technology AB
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002050	A1	20000113	WO 1998-SE1345	19980707
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9883663	A	20000124	AU 1998-83663	19980707
CA 2336739	A1	20000113	CA 1999-2336739	19990707
WO 2000002051	A1	20000113	WO 1999-SE1241	19990707
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9950767	A	20000124	AU 1999-50767	19990707
EP 1095274	A1	20010502	EP 1999-935251	19990707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002519440	T	20020702	JP 2000-558395	19990707
NO 2001000021	A	20010307	NO 2001-21	20010103
US 2005271673	A1	20051208	US 2005-190955	20050728
PRIORITY APPLN. INFO.:			WO 1998-SE1345 A	19980707
			WO 1999-SE1241 W	19990707
			US 2000-519998 B1	20000306

AB A reagent for conjugation to a biomol. for diagnosis and treatment of human and animal conditions and diseases is described, wherein the reagent is a single mol. with at least three functional parts and a) wherein a trifunctional crosslinking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with another mol. having affinity for said ligand; to c) an effector agent, optionally via a linker 2, said effector agent exerting its effects on cells, tissues and/or humorous mols. in vivo or ex vivo; and to d) a biomol. reactive moiety, optionally via a linker 3, said moiety being capable of forming a bond between the reagent and the biomol. The

affinity ligand is especially biotin or a biotin derivative The effector agent is a toxin, an enzyme capable of converting a prodrug to an active drug, an immunosuppressant, an immunostimulant, or a radionuclide-binding agent, with or without the radionuclide.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT